Wells Fargo & Company Ventyx Biosciences, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 15,001 shares of VTYX stock, worth $38,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,001
Previous 12,229
22.67%
Holding current value
$38,252
Previous $30,000
173.33%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VTYX
# of Institutions
134Shares Held
59.2MCall Options Held
180KPut Options Held
179K-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.89MShares$15 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.75MShares$9.56 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.71MShares$9.45 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.54MShares$9.03 Million0.4% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$8.08 Million0.08% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $144M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...